C
51.26
0.41 (0.80%)
| Previous Close | 50.86 |
| Open | 50.99 |
| Volume | 351,853 |
| Avg. Volume (3M) | 975,777 |
| Market Cap | 5,370,766,336 |
| Price / Earnings (TTM) | 40.68 |
| Price / Earnings (Forward) | 27.93 |
| Price / Sales | 9.01 |
| Price / Book | 8.34 |
| 52 Weeks Range | |
| Earnings Date | 13 Feb 2025 - 17 Feb 2025 |
| Profit Margin | 22.56% |
| Operating Margin (TTM) | 25.53% |
| Diluted EPS (TTM) | 1.26 |
| Quarterly Revenue Growth (YOY) | 47.70% |
| Quarterly Earnings Growth (YOY) | 50.50% |
| Total Debt/Equity (MRQ) | 1.06% |
| Current Ratio (MRQ) | 3.70 |
| Operating Cash Flow (TTM) | 144.65 M |
| Levered Free Cash Flow (TTM) | 140.11 M |
| Return on Assets (TTM) | 13.00% |
| Return on Equity (TTM) | 25.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Corcept Therapeutics Incorporat | Bullish | Bullish |
AIStockmoo Score
-0.2
| Analyst Consensus | 1.5 |
| Insider Activity | -1.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.20 |
|
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 11.52% |
| % Held by Institutions | 85.47% |
| 52 Weeks Range | ||
| Median | 80.00 (56.07%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 31 Oct 2024 | 80.00 (56.07%) | Buy | 48.97 |
| 18 Oct 2024 | 80.00 (56.07%) | Buy | 49.75 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| WILSON JAMES N | - | 52.47 | -7,800 | -409,266 |
| Aggregate Net Quantity | -7,800 | |||
| Aggregate Net Value ($) | -409,266 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 52.47 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WILSON JAMES N | Director | 27 Dec 2024 | Disposed (-) | 7,800 | 52.47 | 409,266 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |